Trump's drug pricing EO includes wins on pill penalty reform, faster approvals, and PBM rules, but adds scrutiny on pricing ...

Port Therapeutics and other early biotech startups face funding challenges as investors prefer clinical-stage companies, with ...

A rival bid by Ayrmid for bluebird bio hasn't crossed the finish line, the biotech said, after failing to confirm financing ...

Trump's pharma tariffs prompt companies to assess vulnerabilities. J&J expects $400M in costs. Immunocore's Kimmtrak, Acadia's Nuplazid & Daybue may face impact. Companies highlight US manufacturing ...

Glycomine raises $115M Series C to advance GLM101, a mannose-1-phosphate therapy for PMM2-CDG rare disease, toward Phase 2b ...

Trump signs EO on drug pricing, supports PhRMA reforms for Medicare negotiations timeline, calls for Canadian drug imports, ...

GeneDx will pay up to $33 million in cash upon the deal's expected closing this quarter. GeneDx could spend up to $51 million ...